Silo Pharma (Nasdaq: SILO), a biopharmaceutical company developing novel therapeutics and drug delivery systems, has partnered with Veloxity Labs for bioanalysis support in their ongoing investigational new drug (IND)-enabling GLP toxicology and toxicokinetics study of SPC-15. SPC-15 is an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and is Silo’s lead asset. Silo anticipates initiating the FDA IND process for SPC-15 in 2025, followed by a Phase 1 clinical trial if approved.
This partnership is crucial for advancing SPC-15’s development. Veloxity Labs’ expertise in bioanalysis, specifically their ability to provide rapid turnaround times and high-quality data, will be instrumental in generating the necessary preclinical data package for the IND submission. This accelerates Silo’s timeline towards clinical trials and potentially brings a novel PTSD treatment closer to patients. The selection of an experienced partner like Veloxity demonstrates Silo’s commitment to a robust and efficient drug development process.
Silo’s engagement of Veloxity Labs for bioanalysis services represents a concrete step towards achieving their clinical development goals for SPC-15. This supports their projected timeline of initiating the FDA IND application process in 2025. Success in this preclinical study is critical for securing regulatory approval and advancing SPC-15 into human clinical trials.
This partnership signifies a pivotal advancement for Silo Pharma and the development of SPC-15. A successful IND application would mark a significant milestone, paving the way for clinical investigation and potentially offering a new treatment option for individuals suffering from PTSD. The progress of this partnership will be a key indicator of Silo Pharma’s future prospects.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
